328 related articles for article (PubMed ID: 22287742)
1. Oral metronomic cyclophosphamide with and without methotrexate as palliative treatment for patients with metastatic breast carcinoma.
Gebbia V; Boussen H; Valerio MR
Anticancer Res; 2012 Feb; 32(2):529-36. PubMed ID: 22287742
[TBL] [Abstract][Full Text] [Related]
2. Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer.
Orlando L; Cardillo A; Ghisini R; Rocca A; Balduzzi A; Torrisi R; Peruzzotti G; Goldhirsch A; Pietri E; Colleoni M
BMC Cancer; 2006 Sep; 6():225. PubMed ID: 16978400
[TBL] [Abstract][Full Text] [Related]
3. Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response.
Wong NS; Buckman RA; Clemons M; Verma S; Dent S; Trudeau ME; Roche K; Ebos J; Kerbel R; Deboer GE; Sutherland DJ; Emmenegger U; Slingerland J; Gardner S; Pritchard KI
J Clin Oncol; 2010 Feb; 28(5):723-30. PubMed ID: 20026801
[TBL] [Abstract][Full Text] [Related]
4. Oral metronomic cyclophosphamide and methotrexate plus fulvestrant in advanced breast cancer patients: a mono-institutional case-cohort report.
Aurilio G; Munzone E; Botteri E; Sciandivasci A; Adamoli L; Minchella I; Esposito A; Cullurà D; Curigliano G; Colleoni M; Goldhirsch A; Nolè F
Breast J; 2012 Sep; 18(5):470-4. PubMed ID: 22827581
[TBL] [Abstract][Full Text] [Related]
5. Cyclophosphamide, methotrexate, and chronic oral tegafur modulated by folinic acid in the treatment of patients with advanced breast carcinoma.
Ribas A; Albanell J; Solé-Calvo LA; Gallardo E; Bellmunt J; Vera R; Vidal R; Carulla J; Baselga J
Cancer; 1998 Mar; 82(5):878-85. PubMed ID: 9486577
[TBL] [Abstract][Full Text] [Related]
6. Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer.
Orlando L; Cardillo A; Rocca A; Balduzzi A; Ghisini R; Peruzzotti G; Goldhirsch A; D'Alessandro C; Cinieri S; Preda L; Colleoni M
Anticancer Drugs; 2006 Sep; 17(8):961-7. PubMed ID: 16940806
[TBL] [Abstract][Full Text] [Related]
7. Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma: a randomized phase II trial.
Hainsworth JD; Jolivet J; Birch R; Hopkins LG; Greco FA
Cancer; 1997 Feb; 79(4):740-8. PubMed ID: 9024712
[TBL] [Abstract][Full Text] [Related]
8. Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma: a phase II study.
Bracarda S; Tonato M; Rosi P; De Angelis V; Mearini E; Cesaroni S; Fornetti P; Porena M
Cancer; 2000 Mar; 88(6):1438-44. PubMed ID: 10717628
[TBL] [Abstract][Full Text] [Related]
9. Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes.
Hudis CA; Seidman AD; Baselga J; Raptis G; Lebwohl D; Gilewski T; Currie V; Moynahan ME; Sklarin N; Fennelly D
Semin Oncol; 1995 Dec; 22(6 Suppl 15):18-23. PubMed ID: 8643965
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study.
Rivkin SE; Green SJ; Lew D; Costanzi JJ; Athens JW; Osborne CK; Vaughn CB; Martino S
Cancer; 2003 Jan; 97(1):21-9. PubMed ID: 12491501
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy and concomitant irradiation in inflammatory breast cancer.
Tubiana-Mathieu N; Lejeune C; Bonnier P; Genet D; Adjadj DJ; Berda JF; Muracciole X; Delaby F; Clavere P; Benyoub A; Rhein B; Juin B; Piana L
Anticancer Res; 2001; 21(4B):3061-7. PubMed ID: 11712811
[TBL] [Abstract][Full Text] [Related]
12. A phase I study of pemetrexed (ALIMTA) and cyclophosphamide in patients with locally advanced or metastatic breast cancer.
Dittrich C; Petruzelka L; Vodvarka P; Gneist M; Janku F; Kysela T; Melemed A; Latz J; Simms L; Krejcy K
Clin Cancer Res; 2006 Dec; 12(23):7071-8. PubMed ID: 17145830
[TBL] [Abstract][Full Text] [Related]
13. Salvage therapy with oral metronomic cyclophosphamide and methotrexate for castration-refractory metastatic adenocarcinoma of the prostate resistant to docetaxel.
Gebbia V; Serretta V; Borsellino N; Valerio MR;
Urology; 2011 Nov; 78(5):1125-30. PubMed ID: 22054386
[TBL] [Abstract][Full Text] [Related]
14. Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients.
Bottini A; Generali D; Brizzi MP; Fox SB; Bersiga A; Bonardi S; Allevi G; Aguggini S; Bodini G; Milani M; Dionisio R; Bernardi C; Montruccoli A; Bruzzi P; Harris AL; Dogliotti L; Berruti A
J Clin Oncol; 2006 Aug; 24(22):3623-8. PubMed ID: 16877730
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer.
Sánchez-Muñoz A; Mendiola C; Pérez-Ruiz E; Rodríguez-Sánchez CA; Jurado JM; Alonso-Carrión L; Ghanem I; de Velasco G; Quero-Blanco C; Alba E
Oncology; 2010; 79(1-2):98-104. PubMed ID: 21079407
[TBL] [Abstract][Full Text] [Related]
16. Oral low-dose cyclophosphamide in metastatic hormone refractory prostate cancer (MHRPC).
Nicolini A; Mancini P; Ferrari P; Anselmi L; Tartarelli G; Bonazzi V; Carpi A; Giardino R
Biomed Pharmacother; 2004 Oct; 58(8):447-50. PubMed ID: 15464874
[TBL] [Abstract][Full Text] [Related]
17. Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study.
Lord R; Nair S; Schache A; Spicer J; Somaihah N; Khoo V; Pandha H
J Urol; 2007 Jun; 177(6):2136-40; discussion 2140. PubMed ID: 17509300
[TBL] [Abstract][Full Text] [Related]
18. The impact of schedule on acute toxicity and dose-intensity of high-dose chemotherapy with epirubicin and cyclophosphamide plus colony stimulating factors in advanced breast cancer.
De Placido S; Lauria R; Carlomagno C; Perrone F; De Laurentiis M; Gallo C; Martignetti A; Bellelli T; Limite G; Petrella G; Bianco AR
Int J Oncol; 1999 Aug; 15(2):339-46. PubMed ID: 10402245
[TBL] [Abstract][Full Text] [Related]
19. A Phase I dose escalation trial of continuous infusion paclitaxel to augment high dose cyclophosphamide and thiotepa plus stem cell rescue for the treatment of patients with advanced breast carcinoma.
Zimmerman TM; Grinblatt DL; Malloy R; Williams SF
Cancer; 1998 Oct; 83(8):1540-5. PubMed ID: 9781947
[TBL] [Abstract][Full Text] [Related]
20. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial.
Leonard RC; Lind M; Twelves C; Coleman R; van Belle S; Wilson C; Ledermann J; Kennedy I; Barrett-Lee P; Perren T; Verrill M; Cameron D; Foster E; Yellowlees A; Crown J;
J Natl Cancer Inst; 2004 Jul; 96(14):1076-83. PubMed ID: 15265969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
